Manufacturer
Alvogen, Inc.
21 drugs, 62 product strengths, 21 recalls on record.
Drugs Alvogen, Inc. makes
Levothyroxine-0.4%Generic · 32 makersPharmacies pay from$1.0659 open recallsSertraline+0.8%Generic · 42 makersPharmacies pay from$0.852 open recallsOseltamivir+0.2%Generic · 32 makersPharmacies pay from$9.33Hydrocodone-0.1%Generic · 1 makerPharmacies pay from$2381 open recallEstradiol-0.5%Generic · 39 makersPharmacies pay from$1.8617 open recallsOxycodone+4.5%Generic · 28 makersPharmacies pay from$2.772 open recallsNaproxen-3.7%Generic · 145 makersPharmacies pay from$1.484 open recallsDexamethasone+3.2%Generic · 59 makersPharmacies pay from$1.19Unavailable10 open recallsTestosterone-3.4%Generic · 29 makersPharmacies pay from$35.2068 open recallsBuprenorphine+0.6%Generic · 26 makersPharmacies pay from$8.626 open recallsAmphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate-2.4%Generic · 25 makersPharmacies pay from$6.81Unavailable6 open recallsLisdexamfetamine+6.8%Generic · 18 makersPharmacies pay from$74.56Limited availability8 open recallsNitrofurantoin, macrocrystals / nitrofurantoin, monohydrate-8.1%Generic · 30 makersPharmacies pay from$8.16Buprenorphine / naloxone+8.2%Generic · 22 makersPharmacies pay from$16.17Acetaminophen / oxycodone-0.4%Generic · 23 makersPharmacies pay from$3.532 open recallsPyridostigmine-4.4%Generic · 17 makersPharmacies pay from$7.14Methenamine-0.6%Generic · 17 makersPharmacies pay from$9.33Rasagiline+7.6%Generic · 12 makersPharmacies pay from$13.80Teriparatide-1.4%Generic · 6 makersPharmacies pay from$1,0601 open recallDisulfiram-4.1%Generic · 5 makersPharmacies pay from$52.45Bonsity-1.4%Brand · teriparatidePharmacies pay from$1,060
Recalls
Class IIOngoingJan 21, 2026Levothyroxine Sodium TabletsProduct Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.Alvogen, Inc · D-0259-2026Class IOngoingFeb 26, 2025Fentanyl Transdermal System CIIDefective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.Alvogen, Inc · D-0245-2025Class IITerminatedMar 8, 2023Levothyroxine Sodium TabletsSub-Potent Drug: Out of specification for assay at the 24 month interval.Alvogen, Inc · D-0353-2023Class IITerminatedJul 14, 2021Buprenorphine and Naloxone Sublingual Film 2mg/0.5mgSubpotent drug: Out of specification for assay of naloxone and buprenorphine (low)Alvogen, Inc · D-0649-2021Class IITerminatedAug 21, 2019Nitrofurantoin Monohydrate/Macrycrystals CapsulesFailed dissolution specificationsAlvogen, Inc · D-1722-2019Class IITerminatedAug 21, 2019Macrobid Urinary Tract AnitbacterialFailed dissolution specificationsAlvogen, Inc · D-1723-2019Class ITerminatedMay 15, 2019FENTANYL Transdermal SystemProduct Mix-Up: Customer complaint that their carton labeled as Fentanyl Transdermal Systems, 12 mcg/h contained five patches labeled and containing 50 mcg/h.Alvogen, Inc · D-1277-2019Class IITerminatedJul 12, 2017Clindamycin Injection USPLack of Assurance of SterilityAlvogen, Inc · D-0939-2017Class IITerminatedJul 12, 2017Clindamycin Injection USPLack of Assurance of SterilityAlvogen, Inc · D-0940-2017Class IITerminatedJul 12, 2017Clindamycin Injection USPLack of Assurance of SterilityAlvogen, Inc · D-0941-2017Class IIITerminatedApr 12, 2017Nifedipine Extended-Release TabletsCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0627-2017Class IIITerminatedApr 12, 2017Adalat CCCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0628-2017Class IIITerminatedApr 12, 2017Adalat CCCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0629-2017Class IIITerminatedApr 12, 2017Nifedipine Extended-Release TabletsCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0630-2017Class IIITerminatedApr 12, 2017Nifedipine Extended-Release TabletsCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0631-2017Class IIITerminatedApr 12, 2017Adalat CCCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0632-2017Class IIITerminatedApr 12, 2017Adalat CCCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0633-2017Class IIITerminatedApr 12, 2017Adalat CCCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0634-2017Class IIITerminatedApr 12, 2017Adalat CCCross Contamination with another product:residual powder found in inlet air duct identified as sorafenibAlvogen, Inc · D-0635-2017Class IITerminatedMay 20, 2015NITROFURANTOIN MONOHYDRATE/MACROCRYSTALS CAPSULESFailed Dissolution Specification; 6 month time pointAlvogen, Inc · D-1082-2015Class IITerminatedOct 1, 2014Oxycodone and Acetaminophen Tablets USP 10 mg/325 mgFailed Content Uniformity Specifications - The lot failed to meet the acceptance criteria for Uniformity of Dosage Units at the time of release for the oxycodone...Alvogen, Inc · D-1607-2014
About Alvogen, Inc.
No comments yet. Questions, tips, what worked for you - start the conversation.